Looking for something specific?
At 9M India Limited, trust through quality, transparency, performance.
Antiglaucoma Eye Drop Manufacturer in India
WHO-GMP certified sterile manufacturing of antiglaucoma ophthalmic preparations — prostaglandin analogues, beta-blockers, carbonic anhydrase inhibitors and alpha-2 agonists — for intraocular pressure reduction in glaucoma management.
Key Highlights
-
WHO-GMP
Certified Sterile Ophthalmic Facility -
Sterile Cleanroom
· Grade A/B Manufacturing -
DCGI Approved
Formulations -
Export-Ready
WHAT WE MANUFACTURE
Our Antiglaucoma Ophthalmic eye drop range
Glaucoma is the leading cause of irreversible blindness worldwide — and lifelong daily eye drops
are the cornerstone of treatment.
Our antiglaucoma range covers all major drug classes for IOP
reduction:
- Latanoprost 0.005% Eye Drops — Prostaglandin analogue, first-line for open-angle
glaucoma. Stored refrigerated (2–8°C) - Bimatoprost 0.01% · 0.03% Eye Drops — Prostamide for glaucoma and ocular hypertension
- Travoprost 0.004% Eye Drops — Prostaglandin analogue for IOP reduction
- Timolol Maleate 0.25% · 0.5% Eye Drops — Beta-blocker, oldest class, still widely used
- Dorzolamide 2% Eye Drops — Carbonic anhydrase inhibitor
- Brinzolamide 1% Eye Drops (Suspension) — Carbonic anhydrase inhibitor, better tolerated
than Dorzolamide - Brimonidine 0.1% · 0.15% · 0.2% Eye Drops — Alpha-2 agonist
- Dorzolamide 2% + Timolol 0.5% Eye Drops — Fixed dose combination for IOP reduction
- Latanoprost + Timolol combination Eye Drops — Once daily combination
Enquire Now
WHY 9M INDIA
Antiglaucoma eye drop manufacturing — including cold-chain prostaglandin analogues
-
Sterile ophthalmic manufacturing — classified cleanroom
All ophthalmic preparations at 9M India are manufactured in dedicated sterile cleanroom environments — Grade A fill-finish under Class A laminar airflow, with Grade B background. Environmental monitoring, water for injection (WFI) system validation, 0.22 micron sterile filtration and 100% container closure integrity testing are standard on every batch. No ophthalmic product is manufactured outside these conditions.
-
In-house ophthalmic QC — specialised testing
Sterility · Bacterial endotoxins · Visible particulate matter · Sub-visible particles · pH · Osmolality · Assay (HPLC) · Preservative content · Container closure integrity — all tested in our dedicated ophthalmic QC laboratory. COA issued per batch.
-
Complete documentation within 24 hours
DCGI manufacturing licence · WHO-GMP Certificate · COA · COC · Stability data (ICH Zone II and IVa) · Compatibility studies — available within 24 hours for tender, export registration or CDMO requirements.
WHO WE SUPPLY
Who sources antiglaucoma ophthalmic eye drops from 9M India
-
Ophthalmology departments & eye hospitals
Ophthalmology departments, glaucoma clinics, government and private eye hospitals — antiglaucoma eye drops are chronically prescribed, creating long-term, recurring supply relationships.
-
Private label & contract manufacturing partners
Domestic ophthalmic brands manufacturing antiglaucoma drops through 9M India — Latanoprost 0.005% is a high-value specialty formulation requiring cold chain capability.
-
International export buyers
All export markets — glaucoma is significantly underdiagnosed and undertreated globally, with growing market opportunity as awareness and screening programmes expand in developing countries.
Need WHO-GMP antiglaucoma eye drops manufactured for your market?
Share your requirement — molecule, concentration, pack size and target market. We confirm manufacturing capability, documentation and lead times within 24 hours.
-
WHO-GMP
Certified Facility -
In-House QC
-
Contract &
3PM Available -
DCGI
Approved
Ophthalmic categories
Ophthalmic formulations across 11 categories
We keep answer short
Frequently Asked Questions
Find answers to the most common questions about our products, services, pricing, and policies.
-
01
Yes. 9M India manufactures antiglaucoma eye drops including Timolol (0.25%, 0.5%), Latanoprost 0.005%, Dorzolamide 2%, Brimonidine 0.2% and combination formulations at its WHO-GMP certified sterile ophthalmic facility. Glaucoma is a leading cause of irreversible blindness globally and these formulations are in consistent high demand across all our export markets.
-
02
9M India manufactures antiglaucoma eye drops across all major drug classes: Beta-blockers (Timolol 0.25% / 0.5%), Prostaglandin analogues (Latanoprost 0.005%), Carbonic anhydrase inhibitors or CAI (Dorzolamide 2%), Alpha-2 agonists (Brimonidine 0.2%) and combination formulations (Timolol + Dorzolamide, Timolol + Brimonidine, Timolol + Latanoprost). This covers the full formulary for glaucoma management.
-
03
Yes. 9M India manufactures Latanoprost 0.005% eye drops — a prostaglandin analogue and first-line agent for open-angle glaucoma. Latanoprost is a temperature-sensitive formulation requiring cold chain storage at 2–8°C before opening (stable at room temperature after opening for 4 weeks). 9M India manages cold chain manufacture, storage and dispatch for Latanoprost with documented temperature monitoring records.
-
04
Yes. Timolol is listed on the WHO Model List of Essential Medicines for glaucoma management. 9M India manufactures Timolol 0.25% and 0.5% eye drops and actively supplies institutional buyers, government hospital ophthalmic departments and national glaucoma prevention programmes. Large-volume institutional packaging with complete GMP documentation is available.
-
05
Combination antiglaucoma eye drops contain two active ingredients in a single formulation — improving compliance by reducing the number of drops a patient must instil daily. 9M India manufactures combination antiglaucoma formulations including Timolol + Dorzolamide (beta-blocker + CAI), Timolol + Brimonidine (beta-blocker + alpha agonist) and Timolol + Latanoprost (beta-blocker + prostaglandin analogue).
-
06
Glaucoma is among the leading causes of preventable blindness in Africa, Asia and the Middle East — 9M India's primary export markets. The WHO estimates that 80% of global glaucoma-related blindness is preventable with adequate treatment. Antiglaucoma eye drops represent a consistently high-volume, medically essential export category. Timolol and Latanoprost are especially high-demand across African and Middle Eastern markets.
-
07
Yes. 9M India manufactures Dorzolamide 2% eye drops — a topical carbonic anhydrase inhibitor used as monotherapy or as adjunct to Timolol or prostaglandin analogues in glaucoma management. Dorzolamide is particularly useful in patients with contraindications to beta-blockers (asthma, COPD, bradycardia) and is an important second-line antiglaucoma agent in all our export markets.
-
08
Documentation available includes WHO-GMP Certificate, DCGI Manufacturing Licence, CoPP, batch- wise CoA (sterility, particulate matter, pH, assay), cold chain temperature records for Latanoprost, ICH Zone IVb stability data and CTD/ACTD dossiers on request for all antiglaucoma eye drop formulations.
